Sign In

Ann Lee-Karlon

CEO, President, and Board Member at EpiBiologics

Ann Lee-Karlon is a highly accomplished executive in the biotechnology industry with extensive experience in drug development and corporate leadership. She currently serves as the CEO, President, and Board Member of EpiBiologics, a company focused on developing antibody-based protein degrader therapeutics for various applications including oncology, immunology, neuroscience, and metabolic disorders.12

Career Highlights

EpiBiologics:: Ann joined EpiBiologics as CEO in July 2023, bringing her expertise to advance the company's innovative therapeutic approaches.23

Altos Labs:: Prior to EpiBiologics, she was the Chief Operating Officer at Altos Labs from June 2021 to June 2023. At Altos, she played a crucial role in building the foundation for rapid growth, expanding the company to 500 employees across three global sites.12

Genentech:: Ann spent over 18 years at Genentech, culminating in her role as Senior Vice President. During her tenure, she:

  • Led portfolio strategy and operations for Genentech Research and Early Development
  • Oversaw more than 80 drug development teams
  • Spearheaded major corporate partnerships and programs, including Ocrevus for multiple sclerosis and Rituxan in immunology12

Education and Achievements

Ann Lee-Karlon holds impressive academic credentials:

  • PhD in Bioengineering from UC San Diego (National Science Foundation Fellow)
  • MBA from Stanford University
  • BS in Bioengineering from UC Berkeley12

Her achievements and contributions to the field include:

  • Election as a Fellow of the American Institute for Medical and Biological Engineering
  • Fellow of the inaugural class of the Health Innovators Fellowship
  • Member of the Aspen Global Leadership Network
  • Board member of Eko Health
  • Serves on the Dean's advisory boards for UC Berkeley and UCSD schools of engineering1

Ann's leadership extends beyond her corporate roles. She has served as the president and board chair of the Genentech Patient Foundation and the Association for Women in Science.1

Highlights

May 28 · linkedin

We're heading toward the clinic and would love to hire an experienced Program Manager to join us! Please apply through our website epibiologics.com - here's the link: https://lnkd.in/gCUX526V

Mar 27 · linkedin

EpiBiologics is making rapid progress! See us at #AACR24 on Monday April 8. Our new data demonstrate that EpiTAC extracellular protein degradation has robust activity greater than standard-of-care in multiple preclinical tumor models.     The abstract is now available to view at:  https://lnkd.in/gkDxhsBu    Many thanks to our entire Epi team and AACR presenters: Jonathan Sitrin, Shyra Gardai, Kimberly Hoi, Kenneth Ng. We are inspired to work toward clinically meaningful therapies.   #oncology #medicine #biotechnology #drugdiscovery #innovation

Jim Wells, Alexandra Cantley, David Schenkein, MD, Mitchell Mutz, Ph.D., Jason Coloma, Samuel Bjork, Seiji M., Sakae Asanuma, Michael Kavanaugh, MD, Rami Hannoush, Ph.D., Jennifer Cygan, Amy Liu, Anika Gupta, PhD, Nil Gural, Fabianne Nordenson, Travis Hughes MD, PhD, MPH

Related Questions

What are Ann Lee-Karlon's key achievements at Genentech?
How did Ann Lee-Karlon contribute to the growth of Altos Labs?
What is the mission of EpiBiologics under Ann Lee-Karlon's leadership?
What roles does Ann Lee-Karlon hold outside of EpiBiologics?
What are the main projects Ann Lee-Karlon oversaw at Genentech?
Ann Lee-Karlon
Ann Lee-Karlon, photo 1
Ann Lee-Karlon, photo 2
Add to my network

Location

San Francisco Bay Area